The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
“One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells,” said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. “In the GAPVAC trial we will treat glioblastoma patients with vaccines that are ideal for each patient because they contain personalised antigens.”1
For all patients in the GAPVAC study, researchers will identify genes expressed in the tumour, peptides presented on the human leukocyte antigen (HLA) receptor (i.e. peptides which will be seen by T-cells), cancer specific mutations, and the ability of the immune system to mount a response to certain antigens. Based on this information, two vaccines, called actively personalised vaccines (APVACs), will be constructed and administered following conventional surgery.
The first vaccine will be prepared from a warehouse of 72 targets previously identified by the researchers as relevant for treatment in glioblastoma. These peptides have been manufactured and put on the shelf ready to be vaccinated in patients. Patients will be given a cocktail of the peptides they express and which their immune system can mount a response to.
Singh said: “A patient may express 20 of these 72 targets on their tumour, for example. If we find that the patient’s immune system can mount responses to 5 of the 20 targets, we mix the 5 peptides and give them to the patient. We mix the peptides off the shelf but the cocktail is changed for each patient because it is matched to their biomarkers.”
The second vaccine is synthesised de novo based on a mutated peptide expressed in the tumour of the patient. Singh said: “That peptide is not in our warehouse because it just occurs in this one single patient. The patient receives APVAC-1 and APVAC-2 in a highly personalised fashion in a way that I think has never been done for any patient.”
He added: “GAPVAC has two major goals. One is to show that personalised vaccines are feasible, since this is one of the most complicated trials ever done in cancer immunotherapy. The second is to show that we can mount far better biological responses in these patients compared to vaccination with non-personalised antigens.”
Singh’s previous research has shown that vaccination with non-personalised antigens leads to better disease control and longer overall survival in phase I and phase II clinical studies in patients with renal cell cancer.2
Singh said: “For the non-personalised vaccines we used off-the-shelf peptide targets that were shared by many patients with a particular cancer. Using this approach we have successfully vaccinated patients with renal cell cancer, colorectal cancer and glioblastoma.”
He added: “During this research we identified other targets that appeared in very few patients or even, in extreme cases, in a single patient. Often these rarer peptides are of better quality, meaning they are more specifically seen in cancer cells and occur at higher levels. This led us to start developing personalised cancer vaccines which contain the ideal set of targets for one particular patient. We hope they will be even more effective than the off-the-shelf vaccines.”
The Latest on: Personalised Vaccines
[google_news title=”” keyword=”Personalised Vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalised Vaccines
- Zoetis gets grant for vaccine for protecting porcine animals from prrs viruson April 24, 2024 at 6:08 am
Protect your porcine animals from PRRS virus with Zoetis Inc's patented vaccine method. Administer before weaning for safe, effective protection.
- How pharmacists can help you stay up to date on vaccineson April 18, 2024 at 2:20 pm
Safeway Albertsons pharmacies offer every vaccine approved by the FDA and CDC, and no appointment is required. Sponsored by Safeway Albertsons.
- Chris Oyakhilome: Nigerian pastor pushing malaria vaccine conspiracy theorieson April 17, 2024 at 6:55 pm
One name is repeated frequently by Pastor Oyakhilome: Bill Gates. The billionaire is one of the malaria vaccine's biggest backers, but has also been subject to vaccination conspiracy theories for ...
- Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01on April 17, 2024 at 7:00 am
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial ...
- Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01on April 16, 2024 at 10:00 pm
We eagerly anticipate sharing the one-year clinical readout in Q3 this year and look forward to being one step closer to market with a novel personalized cancer vaccine.” Professor Adnan Khattak ...
- Q&A: When will patients see personalized cancer vaccines?on April 16, 2024 at 10:43 am
Catherine Wu has been a pioneer in a promising approach to fight cancer: vaccines that target specific immune-stimulating molecules, known as immunogenic peptides, generated by the distinct genetic ...
- Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)on April 15, 2024 at 4:27 am
Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE ---- Discovery ...
- A Patient’s View: The Impact Novel Vaccines May Have on Cancer Treatmenton April 11, 2024 at 11:28 am
Elicio Therapeutics, a clinical-stage biotechnology company founded in 2011, is working to disrupt the vaccine space for some of the most aggressive cancers.
- Transgene, NEC Advancing Head and Neck Cancer Vaccine Based on Encouraging Phase I Remission Rateon April 11, 2024 at 11:19 am
At AACR, researchers reported that all 16 patients who received the personalized neoantigen vaccine as an adjuvant therapy remained in remission at follow-up.
- Cancer vaccine with immunotherapy shrinks liver tumors, trial showson April 11, 2024 at 7:59 am
combining immunotherapy with a personalized anti-tumor vaccine increased tumor shrinkage compared to immunotherapy alone.
via Bing News